Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Transformation Hurdles | Avanos Medical faces challenges in its three-year plan, with mixed segment performance and leadership changes impacting its strategic direction |
Financial Resilience | Despite revenue shortfalls, Avanos demonstrates financial strength with cost-saving measures and positive free cash flow generation |
Market Valuation | Explore how Avanos' stock trades at 12x projected 2025 EPS, reflecting cautious optimism amidst ongoing transformation efforts |
Growth Prospects | Delve into Avanos' potential in the Digestive Health segment, offsetting challenges and supporting ambitious 2025 financial targets |
Metrics to compare | AVNS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVNSPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.5x | −5.8x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.7x | 2.7x | 2.6x | |
Price / LTM Sales | 0.8x | 2.9x | 2.9x | |
Upside (Analyst Target) | 13.7% | 75.0% | 51.7% | |
Fair Value Upside | Unlock | 3.4% | 9.5% | Unlock |